(HealthDay) – According to a study published online June 16, the use of certain classes of diabetics from severe COVID-19 infection reduces diabetic mortality.
Anna R from the University of North Carolina at Chapel Hill. Kahkoska, Ph.D. They compared the use of glucagon-like-peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitor (SGLT2i) before the disease with the use before the disease. Severe acute respiratory syndrome Use of a dipeptidyl peptidase-4 inhibitor (DPP4i) for the severity of the outcome of coronavirus-2 infection (SARS-CoV-2). The analysis was performed within 24 months of a positive SARS-CoV-2 polymerase chain reaction test using the GLP1-RA, SGLT2i, or DPP4i protocol for the National COVID Cohort Collaborative Dataset (January 2018-2021 2). Includes 12,446 people identified in (month).
The researchers found that death after 60 days totaled 3.11% but was related to pre-disease drug use (2.06% for GLP1-RA, 2.32% for SGLT2i, 5.67% for DPP4i). Both GLP1-RA and SGLT2i had a lower 60-day mortality compared to DPP4i (odds ratios 0.54 and 0.66, respectively). A similar association was observed between use of both drugs and all-cause mortality. Visit to the emergency room and hospitalization.
“In SARS-CoV-2-positive adults, the premorbid use of GLP1-RA and SGLT2i is associated with a lower mortality rate and other adverse consequences compared to the use of DPP4i. However, DPP4i users were older and generally ill, ”writes the author.
Some authors have shown a financial relationship with the pharmaceutical industry.
DPP4 inhibitors do not increase the risk of inflammatory bowel disease
For more informations:
Summary / full text (subscription or payment may be required)
Copyright © 2021 HealthDay .. all rights reserved.
Quote: Diabetes Drug Types: Serious COVID-19 received from https://medicalxpress.com/news/2021-06-medication-diabetes-affect-severe-covid-.html on June 30, 2021. June) affect, 2021)
This document is subject to copyright. No part may be reproduced without written permission except in fair transaction for personal investigation or research. The content is provided for informational purposes only.
Drug Type For Diabetes May Affect Severe COVID-19 Results Source link Drug Type For Diabetes May Affect Severe COVID-19 Results
